[
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Could Be a Great Choice",
    "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
    "url": "https://finnhub.io/api/news?id=19ed207271b2b4ff27c550e6c84312afac9dfd8bc7087d67772ecf2510c28de6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741967105,
      "headline": "Johnson & Johnson (JNJ) Could Be a Great Choice",
      "id": 133184428,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
      "url": "https://finnhub.io/api/news?id=19ed207271b2b4ff27c550e6c84312afac9dfd8bc7087d67772ecf2510c28de6"
    }
  },
  {
    "ts": null,
    "headline": "Genmab: GEN3014's Demise And Implications For The HexaBody Platform",
    "summary": "Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an analysis of GMAB stock now.",
    "url": "https://finnhub.io/api/news?id=cbc0f55f861454d4980ed5a0f258ea890aacfbb8eee99d8d6091e3e274e9c247",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741962624,
      "headline": "Genmab: GEN3014's Demise And Implications For The HexaBody Platform",
      "id": 133174295,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/483661187/image_483661187.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an analysis of GMAB stock now.",
      "url": "https://finnhub.io/api/news?id=cbc0f55f861454d4980ed5a0f258ea890aacfbb8eee99d8d6091e3e274e9c247"
    }
  },
  {
    "ts": null,
    "headline": "Hostage to Legal Decisions – Here’s Why Jim Cramer Gave Up on Johnson & Johnson (JNJ)",
    "summary": "We recently published a list of Was Jim Cramer Right About These 16 Stocks?. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed 12 months ago during his show on March 18, 2024. On the most recent episode of Mad […]",
    "url": "https://finnhub.io/api/news?id=3de97f087b89691523d045c979ba225d42c0774de337a84077c840d443590da1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741962391,
      "headline": "Hostage to Legal Decisions – Here’s Why Jim Cramer Gave Up on Johnson & Johnson (JNJ)",
      "id": 133184429,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of Was Jim Cramer Right About These 16 Stocks?. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed 12 months ago during his show on March 18, 2024. On the most recent episode of Mad […]",
      "url": "https://finnhub.io/api/news?id=3de97f087b89691523d045c979ba225d42c0774de337a84077c840d443590da1"
    }
  },
  {
    "ts": null,
    "headline": "Zimmer Biomet Focuses on Innovation Amid Growing Competition",
    "summary": "Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention.",
    "url": "https://finnhub.io/api/news?id=7473313943970018112aa3aa3d79531f974cef5f69c01f3e23ee4fc249347670",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741960500,
      "headline": "Zimmer Biomet Focuses on Innovation Amid Growing Competition",
      "id": 133184430,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention.",
      "url": "https://finnhub.io/api/news?id=7473313943970018112aa3aa3d79531f974cef5f69c01f3e23ee4fc249347670"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.",
    "summary": "Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving interest.",
    "url": "https://finnhub.io/api/news?id=647713b5d7a0f754f1eb422329ff7d6f6b53fbeb68dfd1d173d7250004069c1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741944600,
      "headline": "Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.",
      "id": 133184431,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving interest.",
      "url": "https://finnhub.io/api/news?id=647713b5d7a0f754f1eb422329ff7d6f6b53fbeb68dfd1d173d7250004069c1b"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks",
    "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN).",
    "url": "https://finnhub.io/api/news?id=69f320a470a4404d3310a14540a67ad22f533ecb7fe437b1ed3f819aa2ec3b95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741942874,
      "headline": "Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks",
      "id": 133184268,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN).",
      "url": "https://finnhub.io/api/news?id=69f320a470a4404d3310a14540a67ad22f533ecb7fe437b1ed3f819aa2ec3b95"
    }
  },
  {
    "ts": null,
    "headline": "Honeywell's Planned Spinoff And What It Means Amid Macro Volatility",
    "summary": "After a slew of generally successful spinoffs elsewhere in the market, Honeywell looks to split into three units. Read more here.",
    "url": "https://finnhub.io/api/news?id=7f9ef504ea8900a441c218a4ff26dc4e9b73571160920de925aeaf30500f4e7f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741924800,
      "headline": "Honeywell's Planned Spinoff And What It Means Amid Macro Volatility",
      "id": 133167068,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289714229/image_1289714229.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "After a slew of generally successful spinoffs elsewhere in the market, Honeywell looks to split into three units. Read more here.",
      "url": "https://finnhub.io/api/news?id=7f9ef504ea8900a441c218a4ff26dc4e9b73571160920de925aeaf30500f4e7f"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ): “Breakout or Breakdown?” – Jim Cramer Says JNJ Must Fall for Market to Bottom",
    "summary": "We recently published a list of Jim Cramer Discusses These 11 Stocks & Says Trump’s ‘Soft’ On Tariffs Amidst $4 Trillion Wipeout. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In a recent appearance on CNBC’s Squawk on the […]",
    "url": "https://finnhub.io/api/news?id=14ad5ed88a7634f6e275e3d4f719e0a741f1639af70d07c3a19e78062881fe3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741911573,
      "headline": "Johnson & Johnson (JNJ): “Breakout or Breakdown?” – Jim Cramer Says JNJ Must Fall for Market to Bottom",
      "id": 133184433,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Discusses These 11 Stocks & Says Trump’s ‘Soft’ On Tariffs Amidst $4 Trillion Wipeout. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In a recent appearance on CNBC’s Squawk on the […]",
      "url": "https://finnhub.io/api/news?id=14ad5ed88a7634f6e275e3d4f719e0a741f1639af70d07c3a19e78062881fe3d"
    }
  }
]